Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
$1.37
<$0.01(0.15%)
At close: 4:00 PM EST
$1.37
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $3.12
Previous CloseN/A
Volume1.63M
Average Volume (3M)6.17M
Market Cap
$874.55M
Enterprise Value$782.77M
Total Cash (Recent Filing)$380.53M
Total Debt (Recent Filing)$121.92M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 12, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding638,355,300
10 Day Avg. Volume4,855,788
30 Day Avg. Volume6,170,735
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)8.16
Price to Sales (P/S)29.70
P/FCF Ratio-10.43
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit4.95
Enterprise Value/Ebitda-17.45
Forecast
1Y Price Target
$4.00Price Target Upside191.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$260.40M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentGeron is likely positioning itself as a profitable company, as no changes to imetelstat's current clinical development plans were noted.
Commercial EffortsGeron's commercial strategies led to an increase in the number of sites that have utilized Rytelo to over 1000, with a 66% re-ordering rate among accounts.
Strategic RestructuringThe restructuring plan will reduce the workforce by approximately one-third, aiming to streamline operations while maintaining focus on three core priorities.
Bears Say
Reimbursement ChallengesThe biggest barrier to ex-US commercialization is currently reimbursement rates.
Revenue StagnationThe company's Rytelo revenues have been stagnant, with 3Q25 revenues falling below 2Q25 revenues.
Sales EstimatesRytelo sales of $47M were below both our ($58M) and Street ($53M) estimates.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.04 and its highest was $3.12 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $874.55M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Mar 12, 2026 which is in 60 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Nov 05, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.002.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 638,355,300 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -5.217%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (191.97% Upside)
$4.00 (191.97% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-59.94%
12-Months-Change
Fundamentals
Return on Equity
-29.57%
Trailing 12-Months
Asset Growth
27.52%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Company Deck
GERN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with both positive developments in terms of increased prescribing accounts and new patient starts, as well as financial stability. However, there are significant challenges with declining demand, issues with late-line discontinuations, and the need for increased awareness and education on RYTELO's earlier line use.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$4.00
▲(191.97% Upside)
Technical Analysis
Ownership Overview
0.10% Insiders
11.51% Mutual Funds
35.72% Other Institutional Investors
37.59% Public Companies and Individual Investors